Home › Rhabdomyosarcoma
Pag-aaral pangklinika para sa Rhabdomyosarcoma na nagre-recruit sa U.S.
26 pag-aaral para sa Rhabdomyosarcoma ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
- Houston, TX6 pag-aaral
- Memphis, TN6 pag-aaral
- Washington, DC5 pag-aaral
- Salt Lake City, UT4 pag-aaral
- Boston, MA4 pag-aaral
- Philadelphia, PA4 pag-aaral
- Seattle, WA3 pag-aaral
- Aurora, CO3 pag-aaral
- Dallas, TX3 pag-aaral
- Birmingham, AL3 pag-aaral
- The Bronx, NY3 pag-aaral
- Baltimore, MD3 pag-aaral
Ayos sa estado
- Alabama3 pag-aaral
- California7 pag-aaral
- Colorado3 pag-aaral
- District of Columbia4 pag-aaral
- Florida3 pag-aaral
- Maryland4 pag-aaral
- Massachusetts4 pag-aaral
- New York4 pag-aaral
- Ohio5 pag-aaral
- Pennsylvania5 pag-aaral
- Tennessee8 pag-aaral
- Texas9 pag-aaral
- Utah4 pag-aaral
- Washington3 pag-aaral
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma
Nagre-recruitPhase 1
Edad 3 hanggang 39 · Lahat ng kasarian · Na-update Set 29, 2026 · NCT06865664Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
Nagre-recruitPhase 1
24 Months – 18 Years · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06441331Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Nagre-recruitPhase 1/2
Hanggang edad 30 · Lahat ng kasarian · Na-update Set 3, 2026 · NCT06541262A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
Nagre-recruitPhase 3
Hanggang edad 50 · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT07466316Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma
Nagre-recruit
Lahat ng edad · Lahat ng kasarian · Na-update Ago 21, 2026 · NCT07514819Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
Nagre-recruitPhase 1
Edad 1 hanggang 23 · Lahat ng kasarian · Na-update Ago 13, 2026 · NCT07172958Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 6, 2026 · NCT05210374Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Nagre-recruitPhase 1
Edad 1 hanggang 21 · Lahat ng kasarian · Na-update Ago 6, 2026 · NCT04715191Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors
Nagre-recruitMaagang Phase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 31, 2026 · NCT07628634PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Nagre-recruitPhase 1/2
Edad 1 hanggang 30 · Lahat ng kasarian · Na-update Hul 22, 2026 · NCT06721689Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma
Nagre-recruit
Hanggang edad 39 · Lahat ng kasarian · Na-update Hul 13, 2026 · NCT06796543Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
Nagre-recruitPhase 1/2
6 Months – 25 Years · Lahat ng kasarian · Na-update Hun 30, 2026 · NCT06625190Familial Investigations of Childhood Cancer Predisposition
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Hun 17, 2026 · NCT03050268Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
Nagre-recruitPhase 2
Hanggang edad 22 · Lahat ng kasarian · Na-update Hun 15, 2026 · NCT06023641VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
Nagre-recruitPhase 1/2
6 Months – 30 Years · Lahat ng kasarian · Na-update Hun 2, 2026 · NCT04796012B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
Nagre-recruitPhase 1
Hanggang edad 21 · Lahat ng kasarian · Na-update May 19, 2026 · NCT04897321Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
Nagre-recruitPhase 1/2
12 Months – 30 Years · Lahat ng kasarian · Na-update May 19, 2026 · NCT04901702Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies
Nagre-recruitPhase 1
Edad 1 hanggang 30 · Lahat ng kasarian · Na-update Abr 15, 2026 · NCT04308330Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Nagre-recruitPhase 2
Edad 1 hanggang 50 · Lahat ng kasarian · Na-update Mar 13, 2026 · NCT01804634Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
Nagre-recruitPhase 1/2
Edad 12 hanggang 49 · Lahat ng kasarian · Na-update Peb 19, 2026 · NCT06709495Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
Nagre-recruitPhase 1
Edad 1 hanggang 26 · Lahat ng kasarian · Na-update Peb 17, 2026 · NCT07148050HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
Nagre-recruitPhase 1
Edad 1 hanggang 25 · Lahat ng kasarian · Na-update Ene 22, 2026 · NCT04995003Molecular Analysis Of Solid Tumors
Nagre-recruitObservasyonal na pag-aaral
Hanggang edad 25 · Lahat ng kasarian · Na-update Nob 12, 2025 · NCT01050296Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
Nagre-recruitPhase 1
Hanggang edad 21 · Lahat ng kasarian · Na-update Nob 3, 2025 · NCT06198296Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
Nagre-recruitPhase 1
7 Months – 21 Years · Lahat ng kasarian · Na-update Okt 16, 2025 · NCT02508038Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.